Stuart Duty - 10 Jun 2026 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Reporting relationship: Director
Issuer ticker: MIST
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:15:22 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Oliveto, Attorney-in-Fact

Key filing fact

Stuart Duty filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 12 Jun 2026.

Key facts

This page summarizes Stuart Duty's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:15.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001970274 Primary reporting owner

Duty Stuart

Relationship: Director
Address: C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA
Signature: /s/ Joseph Oliveto, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIST transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +77,000
Change %
Price: $0.000000^*
Shares after: 77,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,000
Exercise price: $1.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.